retatrutide clinical trial results 2024 2025 press release New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats This weight-loss drug hasn't been

CARMA1 (also known as caspase recruitment domain 11, CARD11), is a CARD-containing m embrane- a ssociated gu anylate k inase (MAGUK) family protein that is a central regulator of NF-B (nuclear factor kappa-B) activation in lymphocytes

It is bought and sold as a research chemical, not a medication

The total peptide amount does not change

However, the combined gastrointestinal burden may be more challenging to tolerate, and the risk of dehydration leading to acute kidney injury is increased

But the really impressive numbers came from the SURPASS-5 trial, where tirzepatide reduced total cholesterol by 12.9%, LDL cholesterol by 15.5%, and triglycerides by a substantial 24.9%, while increasing HDL cholesterol by 0.9%